JP2007510741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510741A5 JP2007510741A5 JP2006539729A JP2006539729A JP2007510741A5 JP 2007510741 A5 JP2007510741 A5 JP 2007510741A5 JP 2006539729 A JP2006539729 A JP 2006539729A JP 2006539729 A JP2006539729 A JP 2006539729A JP 2007510741 A5 JP2007510741 A5 JP 2007510741A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- alkyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 64
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 18
- 208000002193 Pain Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 230000001684 chronic effect Effects 0.000 claims 8
- 230000036407 pain Effects 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 206010027599 migraine Diseases 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029174 Nerve compression Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 208000005890 Neuroma Diseases 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000004983 Phantom Limb Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 229940127505 Sodium Channel Antagonists Drugs 0.000 claims 2
- 206010049447 Tachyarrhythmia Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 206010043994 Tonic convulsion Diseases 0.000 claims 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 229920001577 copolymer Chemical group 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 229910052744 lithium Inorganic materials 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 230000004112 neuroprotection Effects 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 239000003402 opiate agonist Substances 0.000 claims 2
- 239000003401 opiate antagonist Substances 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000000472 traumatic effect Effects 0.000 claims 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 229940102566 valproate Drugs 0.000 claims 2
- 230000009278 visceral effect Effects 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 0 Cc1nc(*)n[n]1-c1cc(-c2ccccc2)ccc1 Chemical compound Cc1nc(*)n[n]1-c1cc(-c2ccccc2)ccc1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51889003P | 2003-11-10 | 2003-11-10 | |
| PCT/US2004/037280 WO2005047270A2 (en) | 2003-11-10 | 2004-11-05 | Substituted triazoles as sodium channel blockers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510741A JP2007510741A (ja) | 2007-04-26 |
| JP2007510741A5 true JP2007510741A5 (https=) | 2007-12-20 |
Family
ID=34590316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539729A Ceased JP2007510741A (ja) | 2003-11-10 | 2004-11-05 | ナトリウムチャンネル遮断薬としての置換トリアゾール類 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090074890A1 (https=) |
| EP (1) | EP1694654B1 (https=) |
| JP (1) | JP2007510741A (https=) |
| KR (1) | KR20060123739A (https=) |
| CN (1) | CN1922156A (https=) |
| AT (1) | ATE500234T1 (https=) |
| AU (1) | AU2004289694B2 (https=) |
| BR (1) | BRPI0416319A (https=) |
| CA (1) | CA2545254A1 (https=) |
| DE (1) | DE602004031667D1 (https=) |
| IL (1) | IL175522A0 (https=) |
| IS (1) | IS8438A (https=) |
| NO (1) | NO20062676L (https=) |
| NZ (1) | NZ547044A (https=) |
| RU (1) | RU2372339C2 (https=) |
| WO (1) | WO2005047270A2 (https=) |
| ZA (1) | ZA200603583B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| CN1922156A (zh) * | 2003-11-10 | 2007-02-28 | 默克公司 | 作为钠通道阻断剂的取代的三唑 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| KR100808551B1 (ko) | 2006-12-01 | 2008-03-03 | 한국생명공학연구원 | 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| PL2118077T3 (pl) * | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| WO2008124092A2 (en) * | 2007-04-03 | 2008-10-16 | E. I. Du Pont De Nemours And Company | Substituted benzene fungicides |
| CA2703672A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| WO2009055620A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| JP2011504505A (ja) | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤 |
| EP2222638A2 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating inflammation |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CA2867043A1 (en) | 2012-05-03 | 2013-11-07 | Novartis Ag | L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| MY129541A (en) * | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| DE19816880A1 (de) * | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| AU4589701A (en) * | 2000-03-24 | 2001-10-08 | Cocensys Inc | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
| CN1922156A (zh) * | 2003-11-10 | 2007-02-28 | 默克公司 | 作为钠通道阻断剂的取代的三唑 |
-
2004
- 2004-11-05 CN CNA2004800329352A patent/CN1922156A/zh active Pending
- 2004-11-05 AT AT04800897T patent/ATE500234T1/de not_active IP Right Cessation
- 2004-11-05 JP JP2006539729A patent/JP2007510741A/ja not_active Ceased
- 2004-11-05 AU AU2004289694A patent/AU2004289694B2/en not_active Ceased
- 2004-11-05 DE DE602004031667T patent/DE602004031667D1/de not_active Expired - Lifetime
- 2004-11-05 KR KR1020067009120A patent/KR20060123739A/ko not_active Ceased
- 2004-11-05 RU RU2006120426/04A patent/RU2372339C2/ru not_active IP Right Cessation
- 2004-11-05 WO PCT/US2004/037280 patent/WO2005047270A2/en not_active Ceased
- 2004-11-05 CA CA002545254A patent/CA2545254A1/en not_active Abandoned
- 2004-11-05 NZ NZ547044A patent/NZ547044A/en unknown
- 2004-11-05 US US10/578,950 patent/US20090074890A1/en not_active Abandoned
- 2004-11-05 EP EP04800897A patent/EP1694654B1/en not_active Expired - Lifetime
- 2004-11-05 BR BRPI0416319-2A patent/BRPI0416319A/pt not_active Application Discontinuation
- 2004-11-10 US US10/985,592 patent/US7459475B2/en not_active Expired - Lifetime
-
2006
- 2006-05-04 IS IS8438A patent/IS8438A/is unknown
- 2006-05-05 ZA ZA200603583A patent/ZA200603583B/xx unknown
- 2006-05-09 IL IL175522A patent/IL175522A0/en unknown
- 2006-06-09 NO NO20062676A patent/NO20062676L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530694A5 (https=) | ||
| JP2007510741A5 (https=) | ||
| JP2025013344A5 (https=) | ||
| JP2010523476A5 (https=) | ||
| JP2012521429A5 (https=) | ||
| JP2013522368A5 (https=) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2004524312A5 (https=) | ||
| JP2010077141A5 (https=) | ||
| JP2012521428A5 (https=) | ||
| HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
| JP2011511022A5 (https=) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| JP2012525393A5 (https=) | ||
| RU2011109084A (ru) | Терапевтические композиции, содержащие мацитентан | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2014502979A5 (https=) | ||
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2014505017A5 (https=) | ||
| RU2006120426A (ru) | Замещенные триазолы в качестве блокаторов натриевых каналов | |
| JP2021513972A5 (https=) | ||
| JP2003519228A5 (https=) | ||
| JP2010513489A5 (https=) | ||
| EP2150550A4 (en) | NEW CARBAMOYLOXY-ARYL-ALKAN-ARYLPIPERAZIN COMPOUND, PHARMACEUTICAL COMPOSITIONS WITH THE COMPOUND AND METHOD FOR THE TREATMENT OF PAIN, FEAR STATES AND DEPRESSION BY MEANS OF ADMINISTRATION OF THE COMPOUND |